Sunobinop tosylate is under clinical development by Imbrium Therapeutics and currently in Phase II for Insomnia. According to GlobalData, Phase II drugs for Insomnia have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sunobinop tosylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sunobinop tosylate overview

Sunobinop is under development for the treatment of insomnia associated with alcohol cessation, fibromyalgia, overactive bladder and interstitial cystitis pain.The drug candidate is administered orally in the form of tablet. It acts by targeting nociceptin/orphanin-FQ peptide (NOP) receptors. The drug candidate was under development for the treatment of neuropathic pain and postsurgical pain due to third molar extraction. 

Imbrium Therapeutics overview

Imbrium Therapeutics is a clinical stage biopharmaceutical company dedicated to advancing medical science through the development of important new therapies to treat cancer, pain and disorders of the central nervous system.

For a complete picture of Sunobinop tosylate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.